Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8178554 | ALLERGAN | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents |
Jul, 2021
(2 years ago) | |
US7112592 | ALLERGAN | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents |
Jan, 2026
(1 year, 8 months from now) | |
US8471025 | ALLERGAN | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Aug, 2031
(7 years from now) | |
US9695122 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(8 years from now) | |
US8969566 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(8 years from now) | |
US9284314 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7612087 | ALLERGAN | Heterocyclic compounds as inhibitors of beta-lactamases |
Nov, 2026
(2 years from now) | |
US8835455 | ALLERGAN | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Oct, 2030
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 25, 2020 |
New Patient Population(NPP) | Dec 20, 2025 |
Generating Antibiotic Incentives Now(GAIN) | Feb 25, 2025 |
New Indication(I-738) | Jun 22, 2019 |
NCE-1 date: 26 February, 2024
Market Authorisation Date: 25 February, 2015
Treatment: A method of treating a bacterial infection in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp) patients comprising administering an effective amount of a...
Dosage: POWDER;INTRAVENOUS